Latest information on COVID-19
Support teaching, research, and patient care.
My current research areas of interest include developing new strategies for: 1) novel radioligand and radiotracer development for various targets involved in brain cancer, 2) preclinical animal models of glioblastoma, and 3) clinical translation of useful radiopharmaceuticals for early-detection of disease and monitoring therapy.
[18F]DASA-23 and PET Scan in Evaluating Pyruvate Kinase M2 Expression in Patients With Intracranial Tumors or Recurrent Glioblastoma and Healthy Volunteers
This phase I trial studies how well [18F]DASA-23 and positron emission tomography (PET) scan
work in evaluating pyruvate kinase M2 (PKM2) expression in patients with intracranial tumors
or recurrent glioblastoma and healthy volunteers. PKM2 regulates brain tumor metabolism, a
key factor in glioblastoma growth. [18F]DASA-23 is a radioactive substance with the ability
to monitor PKM2 activity. A PET scan is a procedure in which a small amount of a radioactive
substance, such as [18F]DASA-23, is injected into a vein, and a scanner is used to make
detailed, computerized pictures of areas inside the body where the substance is used. Tumor
cells usually pick up more of these radioactive substances, allowing them to be found. Giving
[18F]DASA-23 with a PET scan may help doctors evaluate PKM2 expression in healthy volunteers
and in participants with intracranial tumors or recurrent glioblastoma.
View full details